| Kathryn M Goins, MD | |
|
10800 Midlothian Turnpike, Suite 265, North Chesterfield, VA 23235 | |
| (804) 594-2622 | |
| (804) 594-0915 |
| Full Name | Kathryn M Goins |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 18 Years |
| Location | 10800 Midlothian Turnpike, North Chesterfield, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902028491 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 0101250334 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cjw Medical Center | Richmond, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dogwood Anesthesia Providers Llc | 2769853084 | 133 |
News Archive
Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.
H3 Biomedicine today announced that it has launched research and development operations in Cambridge, Massachusetts. H3 Biomedicine will undertake a comprehensive approach to breakthrough oncology treatments based on two primary principles: 1) the genetics of patients' cancers can reveal drug targets tailored to their cancers and 2) the advances in modern chemistry enable the discovery of new classes of safe and effective drugs against these targets.
Excessive alcohol consumption, as well as obesity leads to the accumulation of fat in the liver, a disease termed fatty liver disease (FLD) or steatosis. FLD is one of the most prevalent diseases in Western societies and affects about 30% of the adult population. Importantly, FLD increases the risk of liver failure, diabetes and cancer and no pharmacological therapies exist for this detrimental disease.
Developing rapid diagnostic tools is key to dealing with the COVID-19 pandemic, and a new electronic-based ‘nose' detector could identify cases in 80 seconds.
Nerve mapping technology allows surgeons to determine whether surgery has been effective for relieving pressure from compressed nerves, which often function poorly and cause sciatica or pain and weakness in muscles supplied by the nerve.
› Verified 2 days ago
| Entity Name | Commonwealth Anesthesia Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548275308 PECOS PAC ID: 7214840453 Enrollment ID: O20031112000526 |
News Archive
Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.
H3 Biomedicine today announced that it has launched research and development operations in Cambridge, Massachusetts. H3 Biomedicine will undertake a comprehensive approach to breakthrough oncology treatments based on two primary principles: 1) the genetics of patients' cancers can reveal drug targets tailored to their cancers and 2) the advances in modern chemistry enable the discovery of new classes of safe and effective drugs against these targets.
Excessive alcohol consumption, as well as obesity leads to the accumulation of fat in the liver, a disease termed fatty liver disease (FLD) or steatosis. FLD is one of the most prevalent diseases in Western societies and affects about 30% of the adult population. Importantly, FLD increases the risk of liver failure, diabetes and cancer and no pharmacological therapies exist for this detrimental disease.
Developing rapid diagnostic tools is key to dealing with the COVID-19 pandemic, and a new electronic-based ‘nose' detector could identify cases in 80 seconds.
Nerve mapping technology allows surgeons to determine whether surgery has been effective for relieving pressure from compressed nerves, which often function poorly and cause sciatica or pain and weakness in muscles supplied by the nerve.
› Verified 2 days ago
| Entity Name | Dogwood Anesthesia Providers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982329900 PECOS PAC ID: 2769853084 Enrollment ID: O20230125000989 |
News Archive
Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.
H3 Biomedicine today announced that it has launched research and development operations in Cambridge, Massachusetts. H3 Biomedicine will undertake a comprehensive approach to breakthrough oncology treatments based on two primary principles: 1) the genetics of patients' cancers can reveal drug targets tailored to their cancers and 2) the advances in modern chemistry enable the discovery of new classes of safe and effective drugs against these targets.
Excessive alcohol consumption, as well as obesity leads to the accumulation of fat in the liver, a disease termed fatty liver disease (FLD) or steatosis. FLD is one of the most prevalent diseases in Western societies and affects about 30% of the adult population. Importantly, FLD increases the risk of liver failure, diabetes and cancer and no pharmacological therapies exist for this detrimental disease.
Developing rapid diagnostic tools is key to dealing with the COVID-19 pandemic, and a new electronic-based ‘nose' detector could identify cases in 80 seconds.
Nerve mapping technology allows surgeons to determine whether surgery has been effective for relieving pressure from compressed nerves, which often function poorly and cause sciatica or pain and weakness in muscles supplied by the nerve.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathryn M Goins, MD 10800 Midlothian Turnpike, Suite 265, North Chesterfield, VA 23235 Ph: (804) 594-2622 | Kathryn M Goins, MD 10800 Midlothian Turnpike, Suite 265, North Chesterfield, VA 23235 Ph: (804) 594-2622 |
News Archive
Achillion Pharmaceuticals, Inc. today reported additional preliminary data from its Phase 1b clinical trial of ACH-1625, which demonstrated that both the third and fourth patient cohorts receiving treatment with ACH-1625 achieved meaningful reductions in HCV RNA after five-day monotherapy, with continued safety and tolerability in patients with hepatitis C.
H3 Biomedicine today announced that it has launched research and development operations in Cambridge, Massachusetts. H3 Biomedicine will undertake a comprehensive approach to breakthrough oncology treatments based on two primary principles: 1) the genetics of patients' cancers can reveal drug targets tailored to their cancers and 2) the advances in modern chemistry enable the discovery of new classes of safe and effective drugs against these targets.
Excessive alcohol consumption, as well as obesity leads to the accumulation of fat in the liver, a disease termed fatty liver disease (FLD) or steatosis. FLD is one of the most prevalent diseases in Western societies and affects about 30% of the adult population. Importantly, FLD increases the risk of liver failure, diabetes and cancer and no pharmacological therapies exist for this detrimental disease.
Developing rapid diagnostic tools is key to dealing with the COVID-19 pandemic, and a new electronic-based ‘nose' detector could identify cases in 80 seconds.
Nerve mapping technology allows surgeons to determine whether surgery has been effective for relieving pressure from compressed nerves, which often function poorly and cause sciatica or pain and weakness in muscles supplied by the nerve.
› Verified 2 days ago
Janine L Thekkekandam, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 10800 Midlothian Tpke, Suite 207, North Chesterfield, VA 23235 Phone: 804-594-2622 Fax: 804-594-0915 | |
Dr. Sanjay Kurichh, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 10800 Midlothian Tpke, Suite 265, North Chesterfield, VA 23235 Phone: 804-594-2622 Fax: 804-594-0915 | |
Lauren Elizabeth Baker, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 10800 Midlothian Tpke # 207, North Chesterfield, VA 23235 Phone: 540-239-7283 | |
Dr. Alexander Flaxman, MD, MSE Anesthesiology Medicare: Medicare Enrolled Practice Location: 1401 Johnston Willis Dr, North Chesterfield, VA 23235 Phone: 804-483-5000 | |
Timothy Patrick Rohman, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 10800 Midlothian Turnpike, Suite 265, North Chesterfield, VA 23235 Phone: 804-594-2622 Fax: 804-594-0915 | |
Alison Game Britton, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 10800 Midlothian Tpke, North Chesterfield, VA 23235 Phone: 805-594-2622 | |
Dr. Scott F Wiese, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 10800 Midlothian Tpke, Suite 265, North Chesterfield, VA 23235 Phone: 804-594-1385 |